Sökning: onr:"swepub:oai:DiVA.org:uu-490818" >
A Brain-Targeting B...
A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice
-
- Rofo, Fadi (författare)
- Uppsala universitet,Institutionen för farmaci
-
- Meier, Silvio R. (författare)
- Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap
-
- Metzendorf, Nicole G., 1979- (författare)
- Uppsala universitet,Institutionen för farmaci,Protein drug design
-
visa fler...
-
- Morrison, Jamie (författare)
- Uppsala universitet,Institutionen för farmaci,Protein drug design
-
- Petrovic, Alex (författare)
- Uppsala universitet,Institutionen för farmaci,Protein drug design
-
- Syvänen, Stina (författare)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Geriatrik
-
- Sehlin, Dag, 1976- (författare)
- Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap
-
- Hultqvist, Greta, 1980- (författare)
- Uppsala universitet,Institutionen för farmaci,Protein drug design
-
visa färre...
-
(creator_code:org_t)
- 2022-08-08
- 2022
- Engelska.
-
Ingår i: NEUROTHERAPEUTICS. - : Springer Nature. - 1933-7213 .- 1878-7479. ; 19:5, s. 1588-1602
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Amyloid-beta (A beta) oligomers and protofibrils are suggested to be the most neurotoxic A beta species in Alzheimer's disease (AD). Hence, antibodies with strong and selective binding to these soluble A beta aggregates are of therapeutic potential. We have recently introduced HexaRmAb158, a multivalent antibody with additional A beta-binding sites in the form of single-chain fragment variables (scFv) on the N-terminal ends of A beta protofibril selective antibody (RmAb158). Due to the additional binding sites and the short distance between them, HexaRmAb158 displayed a slow dissociation from protofibrils and strong binding to oligomers in vitro. In the current study, we aimed at investigating the therapeutic potential of this antibody format in vivo using mouse models of AD. To enhance BBB delivery, the transferrin receptor (TfR) binding moiety (scFv8D3) was added, forming the Bispecific-multivalent antibody (HexaRmAb158-scFv8D3). The new antibody displayed a weaker TfR binding compared to the previously developed RmAb158-scFv8D3 and was less efficiently transcytosed in a cell-based BBB model. HexaRmAb158 detected soluble A beta aggregates derived from brains of tg-ArcSwe and App(NL-G-F) mice more efficiently compared to RmAb158. When intravenously injected, HexaRmAb158-scFv8D3 was actively transported over the BBB into the brain in vivo. Brain uptake was marginally lower than that of RmAb158-scFv8D3, but significantly higher than observed for conventional IgG antibodies. Both antibody formats displayed similar brain retention (72 h post injection) and equal capacity in clearing soluble A beta aggregates in tg-ArcSwe mice. In conclusion, we demonstrate a Bispecific-multivalent antibody format capable of passing the BBB and targeting a wide-range of sizes of soluble A beta aggregates.
Ämnesord
- NATURVETENSKAP -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)
Nyckelord
- Multivalent antibodies
- Bispecific
- A beta
- Oligomers
- BBB
- Mouse models
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas